UDENYCA® is designed to help deliver optimal care and support clinical outcomes
An FDA-approved biosimilar to Neulasta® (pegfilgrastim)
* As of January 2022, the pegfilgrastim prefilled syringe (PFS) marketplace includes ZIEXTENZO® (pegfilgrastim-bmez), Fulphila® (pegfilgrastim-jmdb), and Neulasta® (pegfilgrastim).
UDENYCA® offers cost savings, reliable manufacturing, patient support, and more.
Comprehensive patient support services
Coherus COMPLETE™ provides a suite of patient support services, programs, and industry-leading electronic services designed to
assist with patient access.
Out-of-pocket (OOP) cost for each UDENYCA® dose*
Note: The Coherus COMPLETE™ Co-Pay Assistance Program covers ONLY the cost of UDENYCA® and does not cover any administration or office visit costs.
Receive occasional emails about UDENYCA®, reimbursement, and support services.SIGN UP NOW
References: 1. Data on file. Coherus BioSciences, Inc.; 2022. 2. UDENYCA® (pegfilgrastim-cbqv) package insert. Redwood City, CA: Coherus BioSciences, Inc.; 2021. 3. Neulasta® (pegfilgrastim) package insert. Thousand Oaks, CA: Amgen Inc.; 2021. 4. Data on file. Coherus BioSciences, Inc.; 2021.